Review Article

Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome

Kai Zhan,1 Huan Zheng,1 Jianqing Li,1 Haomeng Wu,1 Shumin Qin,1 Lei Luo,2 and Shaogang Huang1

1The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510000, China
2Department of Gastroenterology, The Second People’s Hospital of China Three Gorges University, Yichang 443000, China

Correspondence should be addressed to Shaogang Huang; huangshaogang@gzucm.edu.cn

Received 3 July 2020; Accepted 14 October 2020; Published 12 November 2020

1. Introduction

Irritable bowel syndrome (IBS) is the most common functional bowel disease, which can be categorized into diarrhea-predominant IBS (IBS-D), constipation-predominant IBS (IBS-C), mixed diarrhea and constipation IBS (IBS-M) and unspecified IBS (IBS-U), mainly symptoms including abdominal pain accompanied by increased defecation, loose stool, or mucus, without obvious organic abnormalities [1, 2]. The worldwide prevalence of IBS is 11.2%; in recent years, the number of patients is increasing, especially the number of young people, which makes the consumption of medical resources for diagnosis and treatment of IBS huge [3, 4]. The disease is mainly treated symptomatically, but it is easy to recur; therefore, patients are worried about suffering from malignant diseases, bearing a huge psychological burden, even causing mental and psychological disorders such as anxiety or depression, and the quality of life is greatly reduced [1].

The pathogenesis of IBS involves extensive and complex disturbances in the gut microbiota-bile acid metabolic axis [5]. Gut microbiota refers to various symbiotic bacteria and other microorganisms growing in the gastrointestinal tract [6, 7]. Under the interaction of host and microorganism, a lot of metabolic substances are produced, including BAs, choline, neurotransmitters, short-chain fatty acids (SCFAs), and other signaling factors and energy substrates, which are involved in gastrointestinal inflammation and carcinogenesis, liver disease, metabolic syndrome, IBS, and chronic diseases [8, 9]. BAs are synthesized in the liver, converted from the primary bile acids to secondary bile acids in the intestine where the microbiota make a significant impact on the process such as deconjugation and dihydroxylation. At the same time, the process will affect the size of the bile acid...
pool, resulting in the occurrence of various diseases [10]. In addition, BAs are not only for inhibiting the growth of gut microbiota and further destroying the stability of intestinal microecology in IBS patients due to excessive generation of cholic acid (CA) and deoxycholic acid (DCA) but also as ligands for the FXR and TGR5, and for inhibiting fibroblast growth factor (FGF) 19, which are related to the pathogenesis of IBS-D [11–14].

In the past few years, most previous studies have paid attention to the field of gut microbiota-bile acid axis in gastrointestinal carcinogenesis and inflammation; few have specifically focused on IBS-D. In this review, we discuss the effects of BAs, gut microbiota, and their interactions on IBS-D depending on current evidence from clinical and animal experiments, and present the potential future directions for the prevention and treatment of IBS-D by targeting the gut microbiota-bile acid axis.

2. Gut Microbiota Dysbiosis and IBS-D

It is the intestine that has the most number of species and densely populated habitat of microorganisms [15]. There are trillions of microorganisms colonized in the human body, which not only maintain our health but also bring us various diseases [8, 16]. In 2011, researchers found that people with IBS had altered gut microbiota via fecal analysis, which opened up possibilities for diagnostic tests and treatments [17]. Soon afterwards, a growing number of studies supported the view that the number and composition of the microbial community in feces and intestinal mucosa of IBS-D patients are different. For example, compared to healthy individuals (8.4 × 10^9 colony-forming units [CFUs]/g feces), IBS-D patients have obviously lower concentrations of aerobic bacteria ((1.4 × 10^7 CFUs)/g; P = 0.002) [18]. Moreover, the recent analysis of fecal samples shows that the most main phyla of microbiota in IBS-D patients were Bacteroidetes (64.64%, vs. healthy controls (HCs) 56.43%), Firmicutes (26.14%, vs. HCs 35.97%), Fusobacteria (5.18%, vs. HCs 1.39%), and Proteobacteria (3.73%, vs. HCs 5.66%), which indicated the percentage of rich phyla Firmicutes was obviously reduced and Bacteroidetes was raised in IBS-D patients [19, 20]. In addition, some bacteria, including Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecalis, could inhibit the growth of intestinal probiotics, such as Bifidobacterium and Lactobacillus [21], which could accelerate the vicious cycle of intestinal flora imbalance that leads to IBS-D. At the genus level, Lachnospira, Ruminococcaceae_UCG003, Lactobacillus, Enterococcus, Weissella, Lachnospiraceae_UCG-010, Oxalobacter, Parasutterella, Turicibacter, and Oceanobacillus were significantly decreased, while Faecalibacterium was increased in IBS-D patients when compared with HCs (P < 0.05) [19]. But Carroll et al. [22] found an obvious reduction in the concentrations of the Faecalibacterium genus in IBS-D patients when compared to HCs. The difference between them may be caused by different original regions of patients, one is from China, the other is from the USA, which tells us the changes in composition and diversity of the gut microbiota in IBS-D patients may be different, even to be the opposite outcome.

The possible reason lies in the small sample size and detection error. Of course, it also reminds us that the response of IBS-D patients in different areas to the same probiotic preparation may be completely different, which depends on the changes of gut microbiota of local patients.

In addition, probiotics play a vital role in the treatment of IBS. In 2018, an open-label, prospective study has shown, compared with patients with non-IBS-D (n = 15), treatment with commercial probiotics for 30 days could obviously improve bowel function satisfaction in patients with IBS-D (n = 11) (P = 0.05) [23]. A double-blind randomized placebo-controlled pilot clinical study indicated that IBS patients’ clinical symptoms, including diarrhea, abdominal pain, bloating, stool frequency, and vomiting, could be obviously relieved after treating with B. coagulans MTCC 5856 at a dose of 2 × 10^9 cfu/day [24]; the effect of it could be involved in producing SCFAs, acetate, butyrate, and propionate [25]. Sjögren et al. [26] observed fecal microbiota transplantation increased gut microbiota diversity (Verrucomicrobia and Euryarchaeota) in patients with IBS-D and significantly improved symptom and quality of life. It is also explained from the side that gut microbiota has a vital relation with IBS-D according to the treatment of probiotics, fecal microbiota transplantation, and rifaximin on IBS-D.

So far, the pathogenesis of IBS is not completely clear, but recent researches have shown that gut microbiota could affect enterochromaffin (EC) cells and thus change the expression levels of 5-hydroxytryptamine (5-HT) [27–29] which can increase visceral sensitivity and trigger IBS-D [30]. At the same time, the metabolites of Clostridium could upregulate the tryptophan hydroxylase (Tph) gene expression in EC cells to promote 5-HT production [31]. A study suggested that Clostridia-rich microbiota of IBS-D could suppress the expression levels of FGF19 in the intestine to promote liver synthesizing and secreting more bile acids [31], which is a process of the inhibition of BA formation in the negative feedback mechanism [32]. Moreover, SCFA, the main metabolites of intestinal flora, can reduce the amount of E. coli, increase the production of lactobacilli, and inhibit the permeability of the intestinal mucosa to protect the function of the intestinal mucosal barrier [33]. According to the current literature, most of the studies focus on the relationship between IBS-D and the number and structure of intestinal flora, while the mechanism of a specific bacteria on IBS-D is less.

3. Bile Acid-Gut Microbiota Axis in IBS-D

3.1. Bile Acid Synthesis, Transport, and Metabolism. BA synthesis from cholesterol takes place in the hepatocytes and occurs through two different pathways. One is the classical pathway, which is regulated by 3 cholesterol hydroxylase enzymes: mitochondrial sterol 27-hydroxylase (CYP27A1), cholesterol 7α-hydroxylase (CYP7A1), and sterol 12α-hydroxylase (CYP8B1) [16, 34]. More than 90% of the total BAs are synthesized by the classical pathway. The other is the alternative pathway, which produces chenodeoxycholic acid (CDCA). The process starts with the hydroxylation of
the cholesterol by CYP27A1, and then, it is transformed by oxyysterol 7α-hydroxylase (CYP7B1) [9, 16]. In the liver, the two most primary BAs (CDCA and CA) are converted to conjugated primary BAs (TCDCA/GCDCA and TCA/GCA) and secreted into the bile after they are conjugated to glycine or taurine [9, 35]. After the bile containing GCA/TCA and GCDA/TCDCA enters the intestine, they will be converted into secondary bile acids including DCA and lithocholic acid (LCA) in two major biotransformations: 7α-dehydroxylation and deconjugation (biochemical reaction process of bile salt hydrolase (BSH) hydrolyzes the conjugated BAs), which are the important processes for gut microbiota to affect the BA metabolism [36, 37]. The detailed process between them is shown in Figure 1.

3.2. Influence of Gut Microbiota on Bile Acids. Gut microbiota is a complicated ecosystem, which consists of over 1000 microbial species and 10^{14} cells, containing genes that are 150 times more than the human genome [34, 35]. According to the latest research, the ratio between microbial cells and...
human cells in the body is 1.3-2.3 : 1, not the previous ratio of 10 : 1 [38, 39]. In fact, over 90–99% of the microbial community in healthy humans and animals are mainly two phyla which are represented by Bacteroidetes and Firmicutes; the others are fewer members in Actinobacteria, Fusobacteria, Proteobacteria, and Verrucomicrobia [39–41]. In physiological condition, gut microbiota contributes to maintaining host health through the production of essential vitamins, food digestion, fighting pathogens, and molecular interaction with the host and plays a vital role in the maturation of the host digestive system. Of course, there are many kinds of microbiota among them which play a vital influence on the process of producing secondary BAs in the intestine, such as Listeria monocytogenes, B. vulgatus, Lactobacillus, Clostridium perfringens, Bifidobacterium, Bacteroides fragilis, and the genus Clostridium. The detailed relationship between these bacteria and IBS is shown in Table 1.

In humans, gut microbiota is involved in the secondary BA production via deconjugation, 7α-dehydroxylation, oxidation, epimerization, desulfation, and esterification reactions, respectively; two important reactions of them are deconjugation and 7α-dehydroxylation [36, 37]. The enzymatic hydrolysis of the C-24 N-acyl amide carried out by BSH in the small intestine is called as deconjugation [42, 43]. BSH activity can be highly expressed by commensal bacteria inhabiting in the small and large intestine, including Bacteroides, Clostridium, Lactobacillus, Bifidobacterium, Enterococcus, and Listeria [9, 16, 44–47]. Apart from deconjugation, BAs undergo additional biotransformation; it is the bacterial 7α-dehydroxylation that converts nearly all CA

| Bacteria          | Reactions                      | Percentage in IBS | Citations                    |
|-------------------|--------------------------------|-------------------|------------------------------|
| Lactobacillus     | Lower                          | [35, 164–167]     |
| Bifidobacterium   | Lower                          | [164, 166, 168–171]|
| Listeria          | —                              | [9, 172]          |
| B. vulgatus       | Deconjugation                  | —                 | [172–174]                    |
| Bacteroides       | Higher                         | [9, 16, 20, 47]   |
| Clostridium       | Higher                         | [9, 16, 47]       |
| Enterococcus      | Higher                         | [22, 34]          |
| Clostridium       | Higher                         | [10, 12–14]       |
| Eubacterium       | 7α-Dehydroxylation             | lower             | [9, 34, 175]                 |
| Peptostreptococcus| —                              | [47, 172]         |
| Escherichia       | Higher                         | [35, 172]         |
| Bacteroides       | Higher                         | [20, 176]         |
| Clostridium       | Higher                         | [16, 42, 49, 172, 177] |
| Eubacterium       | Oxidation and epimerization    | lower             | [34, 175]                    |
| Eggerthella       | —                              | [172]             |
| Ruminococcus      | Higher                         | [172, 178, 179]   |
| Bifidobacterium   | —                              | [47, 178]         |
| Lactobacillus     | Lower                          | [35, 47, 164, 165–167] |
| Clostridium       | Higher                         | [47, 180, 181]    |
| Peptococcus       | Higher                         | [22, 47, 182]     |
| Fusobacterium     | Desulfation                    | Lower             | [47, 175, 183]               |
| Proteobacteria    | Higher                         | [184, 185]        |
| Pseudomonas       | —                              | [172]             |
| Bacteroides       | Esterification                 | Higher            | [34, 176]                    |
| Methanogens       | Lower                          | [186, 187]        |
| Veillonella       | Higher                         | [5, 178, 184]     |
| Faecalibacterium  | Lower                          | [5, 184]          |
| Lachnospiraceae   | Others                         | Higher            | [184]                        |
| Actinobacteria    | Lower                          | [184, 185]        |
| Enterobacter      | Higher                         | [35]              |
| Erysipelotrichaceae| Lower                         | [178]             |

Abbreviations: IBS: irritable bowel syndrome.
(with hydroxy groups at C-3, C-7, C-12) and CDCA into DCA and LCA in the colon, respectively [47, 48]. It has been confirmed that Clostridium and Eubacterium are involved in 7α-dehydroxylation. The 16S rRNA sequence analyses in recent years have shown the genus Clostridium is involved in the reaction, including C. hiranonis, C. scindens, C. hylemonae (Clostridium cluster XIVa), and C. sordelli (Clostridium cluster XI) [26, 42, 48–50]. But some research indicated that C. hylemonae (Clostridium cluster XIVa) was the only distinct members of Clostridium to undergo this reaction [42, 47, 51]. Therefore, further research is needed in the field of intestinal flora. Moreover, Eggerthella, Clostridium, Bacteroides, Peptostreptococcus, Ruminococcus, Eubacterium, and Escherichia participate in catalyzing epimerization and oxidation of the hydroxyl (OH) groups at C3, C7, and C12 [9, 52, 53]. At the same time, a research indicated, compared to the conventional mice (88 ± 1.7% relative to the total BA), germ-free mice hardly detected secondary BAs (1.8 ± 0.2%) in fecal samples, but the latter (86.8 ± 0.8%) had a higher proportion of conjugated BAs [54]. This is one of the strong evidence for the involvement of gut microbiota in deconjugation and dehydroxylation of bile acids.

3.3. Influence of Bile Acids on Gut Microbiota. BAs serve as environmental cues and nutrients to microbes, but they also have a direct antimicrobial on gut microbiota and can cause disease by regulating gut microbiota. A number of studies have suggested higher BA concentration exert cytotoxicity, causing apoptosis, inducing proinflammatory actions and DNA damage, producing necrosis, and involving functional gastrointestinal disorders (FGID) [55–58]. Some researches have revealed that DCA is one of the most effective antimicrobial bile, its bactericidal activity is 10 times than that of CA, and it can seriously inhibit the growth of gut microbiota such as lactobacilli, Clostridium perfringens, bifidobacteria, and Bacteroides fragilis [59, 60]. CA can decrease beneficial bacteria Roseburia, Lactobacillus, and Ruminococcus [61]. Feeding CA to rats raised the proportion of Firmicutes/Bacteroidetes, simplified the diversity of gut microbiota, and increased the growth of some microorganisms in the classes Erysipelotrichi and Clostridia which mainly includes the genus Allobaculum and the genus Blautia, respectively [12, 62]. The evidence indicated that nearly 68% of patients with IBS-D had increased total fecal BAs or bile acid malabsorption [55, 63]. In addition, the genes klotho B (KLB) and fibroblast growth factor receptor 4 (FGFR4) related to BAs make a significant influence on accelerating small intestinal or colonic transit in IBS-D [64, 65]. Dior et al. [66] found that primary BAs were obviously increased and secondary BAs were obviously decreased in IBS-D patients’ serum and stool compared to healthy subjects. At the same time, the BA receptors TGR5 and FXR can make a vital influence on metabolic disorders and promote the production of secondary BAs in the gut [10]. In animal experiments, people found that DCA could induce colon net water secretion and have an excitatory effect on motility in the rat proximal colon [67, 68]; that is one of the reasons of IBS-D [69, 70]. Oral administration of CDCA could increase defecation frequency and accelerate colonic transit in a dose-dependent manner [69, 71, 72].

4. Bile Acid-Activated Receptors and Signals

BAs, acting as signaling molecules, also play a significant role in the human body.

They could regulate various physiological functions via interaction with FXR, vitamin D receptor (VDR, NR1H1), TGR5, pregnane X receptor (PXR, NR1I2) and constitutive androstane receptor (CAR, NR1I3) [11–13, 73, 74], and cell signaling pathways such as extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) [75]. BAs can bind to different nuclear receptors and activate them in a rank order. For example, in most human liver and colon cell lines, FXR can be activated in a rank order of CDCA > DCA > LCA > CA. While the rank order of TGR5 is different, one is LCA > DCA > CDCA > CA for unconjugated BAs [76], the other is TLC > LCA > GLCA > TDCA > DCA > GDC > TCDCA > CDCA > GCDCA > TCA > CA > GCA for both conjugated and unconjugated BAs [77]. PXR and VDR are activated only by LCA. The following is a review of TGR5, FXR, and their related pathways (Figure 2).

4.1. Gut Microbiota-FXR Axis. The gut microbiota regulates FXR signaling via intervening BA metabolism and the production of secondary BAs. FXP is the main BA senor and highly expressed in the ileum and liver [78]. It takes part in many biochemical reaction processes, including regulating the bile acid homeostasis, lipid, and glucose metabolism [36]. In terms of bile acid synthesis in humans, it is tightly regulated by the negative feedback inhibition through FXR primarily by two downstream target genes, FGF19 (FGF15 in mice) in the ileum and small heterodimer partner (SHP) in the liver [79]. Studies have indicated that FXR and its two downstream target genes (SHP and FGF15) are highly expressed in the gut of the conventionally raised (CONVR) mice when compared to germ-free (GF) mice [80, 81]. In turn, the circulating FGF19 decreases the expression of liver cholesterol 7α-hydroxylase and BA synthesis [82]. Moreover, the fecal BA excretion and hepatic BA synthesis in mice have been increased by changing the gut microbiota profiles using probiotics, the mechanism of which has a close connection with the inhibition on the enterohepatic FXR–FGF15 axis [83]. Sayin et al. [80] found that the expression levels of SHP and FGF15 induced by microbiota were completely inhibited in FXR−/− mouse ileum, which directly evaluates the influence of gut microbiota on the target downstream of FXR. The new research shows that Clostridia-rich microbiota can result in an excessive BA production by suppressing the intestinal FGF19 expression in IBS-D patients [14]. On the other hand, BAs make an indirect influence on gut microbiota via regulating the expression levels of FXR. It has been pointed out recently that FXR activated by BAs could upregulate some gene expression (such as Ang1, iNos, and Il18) to inhibit the bacterial overgrowth and mucosal injury in the gut [84]. With the deepening of research, more and more people have also realized the relationship between FXR and IBS-D.
Recent researches have shown that FXR mRNA had higher expression levels in the rectosigmoid mucosa of IBS-D patients [85, 86], while Horikawa et al. [87] found it was also obviously increased in IBS patients’ ileum, but not in the rectum, duodenum, and cecum. Given the difference of the study, we considered that the sample of Horikawa et al. was small (15 IBS patients, including 8 IBS-D patients, 7 IBS-M patients). So, further research needs to be done. In animal research, compared to wild-type mice (FXR+/+), Vavassori et al. [88] observed a mild to moderate cellular infiltration of the colonic mucosa lamina propria and increased mRNA expression of IL-1β, TGFβ1, and TNF-α in FXR−/− mouse colons. We can infer that the FXR gene ablation leads to the dysregulation of intestinal immunity and proinflammatory, which make a significant influence on the mechanism of IBS. In addition, visceral hypersensitivity is involved in IBS-D. Li et al. [89] demonstrated that visceral hypersensitivity induced by prolonged colonic BA stimulation was involved in the FXR/Nerve growth factor (NGF)/transient receptor potential vanilloid (TRPV) 1 axis. On the other hand, FXR also has a connection with the gut microbiota and autophagy. For example, FXR-deficient mice could increase the expression levels of Firmicutes and decrease the expression levels of Bacteroidetes [81], which is consistent with the changes of gut microbiota in IBS-D according to the recent study. Moreover, Lee et al. [90] found FXR could bind to shared sites in autophagic gene promoters to suppress autophagy in mice. In the gut-specific autophagy-

Figure 2: Summary of the possible signaling pathway between gut microbiota-bile acids axis and IBS-D. The metabolic disorder of the gut microbiota-bile acid axis could lead to the higher secretion levels of secondary BAs, which activate a series of signaling pathways in the intestinal epithelium, resulting in VH, damage of intestinal mucosal barrier function, increased intestinal motility, and increased intestinal bile acid excretion, thus promoting the occurrence of IBS-D. On the one hand, the reduced expression of FXR can not only upregulate the NGF/TRPV1 signaling pathway to cause VH but also downregulate FGF19/15 that can regulate the JNK1/2 and ERK1/2 signaling pathway to make an inhibition on intestinal barrier function and promote autophagy. On the other hand, the increased secondary BAs can activate TGR5 on EC cells to up-regulate the expression of 5-HT and CGRP, causing increased colonic motility. At the same time, 5-HT could upregulate the release of 5-HT3R to cause VH and transmit stimulus to the spinal cord, the process of which may be involved in the brain-gut interaction. Abbreviations: BAs: bile acids; FXR: farnesoid X receptor; NGF: nerve growth factor; TRPV1: transient receptor potential vanilloid 1; VH: visceral hypersensitivity; FGF19/15: fibroblast growth factor (FGF) 19/15; JNK: c-Jun N-terminal kinase; ERK: extracellular signal-regulated kinase; TJ: tight junction; CYP7A1: cholesterol 7α-hydroxylase; SHP: small heterodimer partner; TGR5: G-protein-coupled bile acid receptor 1; 5-HT: 5-hydroxytryptamine; 5-HT3R: 5-hydroxytryptamine 3 receptor; CGRP: calcitonin gene-related peptide; EC: enterochromaffin; SCFA: short-chain fatty acids; ENS: enteric nervous system; CNS: central nervous system; VDR: vitamin D receptor.
related 5 knockout (Atg5−/−) mouse model, researchers found that the composition and richness of the gut microbiota were changed, with increasing Candidatus Athromitus and the Pasteurellaceae family and decreasing the Lachnospiraceae and Akkermansia muciniphila family [91]. Therefore, we could infer that the potential connections between autophagy and gut microbiota regulated by BA-activated receptors could exist, which may contribute to a profound influence on the pathological mechanism research of IBS-D. Of course, some researches pay attention to the FXR downstream target genes FGF19/15, which are involved in abnormal BA metabolism so as to IBS-D. FGF19/15 induced by FXR in the ileum binds to the FGF receptor 4 (FGFR 4)/β-klotho heterodimer complex in the liver, which activates the JNK1/2 and ERK1/2 pathways to inhibit the expression of the CYP7A1 gene [92, 93] to regulate BA metabolism. In IBS-D patients with excess total BA excretion in feces (≥10.61 μmol/g), the concentration of serum FGF19 was decreased when compared with the healthy controls [14]. Moreover, Vijayvargiya et al. [94] found fasting serum FGF19 levels had good specificity and negative predictive value by testing 101 patients with IBS-D. Further researches indicated the activation of the JNK pathway could lead to the degradation of the tight junction protein, while the activation of the ERK1/2 pathway could promote the assembly of tight junction protein and repair the solidified intestinal mucosal barrier [95–100]. In addition, Dai et al. [101] confirmed that VSL#3 probiotics could activate the ERK signaling pathway to increase the expression levels of tight junction protein in vivo and in vitro so as to protect the epithelial barrier. We have previously discussed the important role of the intestinal mucosal barrier in IBS-D; according to these results, we consider that the gut microbiota-BAs-FXR-FGF19/15-JNK/ERK pathway may be an attractive potential mechanism for IBS-D.

4.2. TGR5. TGR5 is another BA-responsive receptor with high expression in the intestine L. tissues, gallbladder epithelial cells, gallbladder smooth muscle cells, hepatic sinusoidal endothelial cells, Kupffer cells, and immune cells [76, 77, 102, 103]. It can be activated by the primary and secondary BAs, and it mainly sends its signal by increasing the intracellular concentrations of cyclic AMP (cAMP), resulting in stimulating the expression of downstream cAMP-dependent protein kinase A (PKA) [104]. Though the exact relationship between TGR5 and IBS-D is still unknown, we will review the most relevant pathological mechanism of IBS-D at present.

In the gastrointestinal tract, TGR5 induced by BAs protects the intestinal barrier function and reduces inflammation [105]. When compared to WT mice, TGR5−/− mice had an abnormal morphology of the colonic mucous and an increased intestinal permeability [106] which might cause their raising susceptibility to IBS-D. Intestinal epithelium mainly consists of adherens junction, desmosome, and tight junction; among them, tight junctions are multiprotein complexes including claudins and occludins proteins. Moreover, zonula occludens 1 (Zo1) and Zo2 are significant to tight junction assembly and maintenance [107]. Fewer researches focus on the tight junction protein and TGR5 in IBS-D, while we can find a little literature about other diseases. For example, Abu-Farsak et al. [108] found there was a positive correlation between the expression of Claudin-2 and TGR5 in the esophageal tissue, and the expression levels of claudin-2 were significantly increased from normal squamous mucosa to columnar cell metaplasia, Barrett’s esophagus, and low- and high-grade dysplasia to esophageal adenocarcinoma. On the other hand, Yang et al. [109] demonstrated that TGR5 activated by BAs could activate the JNK pathway. It was discussed above that the JNK pathway could lead to the degradation of tight junction protein [95–100]. Therefore, we could infer from these results that excessive BAs in the gut may induce the expression of TGR5, activate the downstream JNK signal pathway, increase the permeability of mucosa, and eventually damage the mucosal barrier. If so, the result is contradictory like the studies of claudin-2; it needs much more experiments to confirm. At the same time, the gut microbiota and their metabolic products could directly regulate the expression of tight junction protein to change the enteric mucosal permeability and, eventually, achieve the ability to maintain the integrity of the intestinal epithelial barrier [110, 111]. In turn, alternations in the composition and richness of the gut microbiota can also cause an increase in mucosal permeability and a damage to the intestinal epithelial barrier function [112].

Some researches indicated that TGR5 involved BA-induced gastrointestinal motility [113, 114]. Up to now, the action is stimulatory or inhibitory and still exists controversy. In vitro, Alemi et al. [115] reported that various TGR5 agonists could regulate peristalsis of colon full-thickness segments in wild-type (WT) mice, but there was no influence in TGR5−/− mice. And in vivo, TGR5−/− mice had slowed colonic transit, had reduced frequency of defecation, and had lower fecal water content compared with WT mice and TGR5-transgenic mice, even constipation. Moreover, TGR5-transgenic mice had accelerated colonic transit and increased 1.4-fold pellet excretion. In the colon, BAs activate TGR5 on enterochromaffin (EC) cells to upregulate the expression of 5-HT and on enteric neurons to upregulate the expression of calcitonin gene-related peptide (CGRP). TGR5 and CGRP could promote colon peristalsis [116]. But some studies have shown TGR5 could slow small intestinal motility and may serve in the “ileal brake,” a mechanism that slows the intestinal transit during digestion so as to improve the absorption of nutrients [117, 118]. Further evidence has shown that BA-induced TGR5 in colon epithelial may contribute to limiting the fluid secretion into the lumen in order to prevent its excessive loss from feces [117]. Consistent with their researches, Poole et al. [118] found the expression level of TGR5 mRNA was widely increased around the GI tract, particularly in the enteric ganglia, and prominently expressed by inhibitory motor neurons; its activation inhibited intestinal contractility and slowed gastric emptying and small intestinal transit. The effect may involve in the nitrergic mechanism, and/or GPR/cAMP pathway regulating muscle relaxation [118, 119]. Moreover, direct evidence suggests there is a connection between the TGR5 genotype variations (rs11554825) and small intestinal transit in IBS-D patients [65]. Therefore, from one aspect of these results, we may consider BAs-TGR5-(5-HT)/CGRP-
accelerates the colon peristalsis axis and plays a vital role in IBS-D.

TGR5 mRNA is expressed on astrocytes and neurons in the mouse and human brains [120]. It is discussed above that TGR5 could upregulate the expression of 5-HT on EC cells in the GI tract [116], and there are 95% of the body’s 5-HT stored in EC cells and enteric neurons, and only 5% in the central nervous system (CNS) [121]. The evidence has shown 5-HT is involved in the neuroendocrine pathway within the brain-gut-microbiome axis via the essential amino acid tryptophan (Trp) [122, 123]. Further research indicated the expression of plasma 5-HT and Trp levels in germ-free mice were prominently decreased compared to conventionally colonized mice [25, 124]. Moreover, current evidence has shown that microbiome regulated the CNS which occurs mainly via the neuroimmune and neuroendocrine mechanisms [125–127]. This process is involved in some microbiobially derived molecules, such as tryptophan metabolites, SCFAs, and secondary bile acids [25, 29, 125]. Therefore, we can see the complex relationship among intestinal microbiota, TGR5, and 5-HT in the brain-gut-microbiome axis from these results. In addition, Lacy et al. [3] show the disturbances in the brain-gut function were one of the most important mechanisms in IBS. A retrospective analysis has shown 5-HT and 5-hydroxytryptamine receptor 3 (5-HT3R) were both prominently expressed in the intestinal mucosa tissue of IBS-D patients when compared with healthy subjects [128]. At the same time, 5-HT3R antagonists contributed to suppress urgency, alleviate symptoms, and prolong the intestine transit in IBS-D, while 5-HT3R agonists could promote intestinal motility, and accelerated transit in IBS-C patients [129]. The possible mechanisms are the activation of 5-HT which promotes visceral hypersensitivity causing irritable bowel syndrome [130, 131]. So, with the emerging evidences that occurred, the brain-gut-microbiome axis may become a new hot topic in IBS.

5. Targeting Microbiota-Bile Acid Axis for the Treatment of IBS-D

5.1. Probiotics. Due to their widespread influence on intestinal cells and tissue and their vital role in many physiological processes, the microbiota-bile acid axis may contribute to providing a potential therapeutic direction in the treatment of IBS-D. A number of recent systematic reviews of the literature and meta-analyses have concluded that probiotics have a limited but significant therapeutic effect over placebo on IBS symptoms [132–134]. Probiotic VSL#3 consisted of 8 Gram-positive bacteria strains (1 species of Streptococcus thermophilus, 3 species of Bifidobacterium, and 3 species of Lactobacillus). Degirolamo et al. [83] show the evidence that VSL#3 probiotics could promote ileal BA deconjugation and fecal BA excretion and increase hepatic BA neosynthesis in vivo by downregulation of the gut-liver FXR-FGF15 axis. Moreover, probiotic VSL#3 makes a vital influence on decreasing visceral sensitivity in patients with IBS [135, 136], resetting colonic expression level of subsets of genes regulating inflammation and pain and reducing visceral pain perception in the murine model of IBS [137]. Some other studies indicated the L. acidophilus NCFM and L. johnsonii strain 100–100 could be involved in the BA metabolism owing to the ability of hydrolyzing bile salts [138, 139]. A randomized, double-blind, placebo-controlled trial in Vietnamese patients with unconstipated IBS indicated the new combination of Lactobacilli including L. salivarius, L. plantarum, and L. paracasei could relieve the abdominal symptoms [140]. The mechanisms of the effect of probiotics in IBS are only partially known. Researches show that the different effects of different strains of probiotics on IBS patients, such as Bifidobacterium longum subsp. longum NCC3001 (BL) could change brain activity and decrease depression scores [141], Bifidobacterium lactis DN-173-010 could accelerate colonic transit in IBS-C patients [142], and Escherichia coli strain Nissle 1917 (EcN) could decrease the visceral pain caused by IBS [143]. According to the new systematic review, in which the data was conducted in Medline (PubMed) from 2014 to March 2019, it has more significant beneficial effects on improving IBS symptoms than using multistrain probiotics supplements for 8 weeks or more when compared with a monostrain probiotics supplement [144], but patients treated with probiotics had a higher incidence of any adverse event (relative ratios (RR) 1.21; 95% confidence interval (CI) 1.02-1.44) [145]. Therefore, the dose and duration of treatment of multistrain probiotic supplementation on IBS patients should be established via further long-duration randomized controlled trials (RCTs).

5.2. Fecal Microbiota Transplantation (FMT). Fecal microbiota transplantation (FMT) may act as a potential therapy to treat IBS. Since the first RCT on FMT treatment for IBS has been started in Norway in 2017 [146], the exploration of FMT for IBS has never been stopped. In their study, 65% of the participants who received FMT treatment and 43% of the participants who received placebo for 3 months reduced more than 75 points of the IBS-severity scoring system (P = 0.049), which show that the treatment group had a better effect than the placebo group. Moreover, in 2019, Johnsen et al. also confirmed that IBS-related quality of life and fatigue in patients with nonconstipated IBS were significantly relieved after treating by FMT [147]. In 2020, a clinical study has shown the symptoms (diarrhea, bloating, and abdominal pain) of IBS-D patients who were treated with donor FMT were correlated with the change in uroguanylin immunoreactive cell density in the duodenum compared with controls [148]. In addition, Sun et al. [149] found FMT could alleviate small intestinal transit and reduce the concentration of DCA and CA in the high-fat diet (HFD-) fed rat model, which may be involved in downregulating the expression level of TPH1 and reducing the concentration of serotonin in the gut. On the other hand, some evidence has shown that FMT had no obvious therapeutic effect on IBS. In 2019, a systematic review and meta-analysis has shown there was no significant difference in improving the symptoms of IBS after 12 weeks of FMT treatment compared with placebo (RR 5 0.93; 95% CI 0.48–1.79) and had lower evidence in the grading of recommendation development, assessment, and evaluation quality of the body [150]. Moreover, 59.5% (95% CI 49.1–69.3) of IBS patients showed an obvious improvement of the symptoms in single-arm trials, while there was no
significant improvement in RCTs compared to control (RR1/4 0.93 (95% CI 0.50–1.75)) [151]. Additionally, studies reported that it was too limited to draw sufficient conclusions depending on the current data on FMT in treating IBS and might occur some adverse reactions during treating with FMT, including Gram-negative bacteremia, death, and perforation/tear [152–154].

5.3. Cholestyramine. As what has been discussed above, about 68% of patients with IBS-D have abnormal bile acid absorption, of which 10% have severe idiopathic bile acid malabsorption (IBAM) (SeHCA T<retention < 5%), 32% have moderately severe I-BAM (SeHCA < 10%), and 26% have I-BAM at SeHCA T<retention < 15%[29], and they could increase the synthesized and excreted levels of BAs compared to the patients with IBS-C or healthy volunteers [155]. In 2016, the American Gastroenterological Association (AGA) has recommended bile salt sequestrants as one of the effective drugs in the treatment of IBS-D [65]. It could increase the fecal BA excretion via regulating the enterohepatic bile acid circulation, thereby upregulating the synthesis of BAs in the liver [156]. The most commonly used bile acid sequestrant is cholestyramine [157], which can increase cecal SCFA production and downregulate the mRNA expression level of intestinal SHP in rats [158, 159]. While SCFA takes part in the process that microbiome regulates the CNS causing the intestinal SHP in rats [158, 159]. Therefore, cholestyramine might be involved in regulating the gut microbiota-bile acid axis to treat IBS-D.

6. Genetic Engineering of Bacteria

Since the rapid development of microbial technology, the production of probiotics with satisfying specific needs has been a close reality. It was reported that a phase I clinical trial with transgenic Lactococcus lactis expressing mature human interleukin-10 instead of thymidylate synthase for the treatment of Crohn was successful to improve the clinical scores of these patients [160]. Moreover, Bacteroides fragilis plays a vital influence on the deconjugation process of BAs [80] and is more abundant in IBS patients [161]. The polysaccharide A (PSA-) producing Bacteroides fragilis could restore normal cytokine production by correcting the TH1/TH2 imbalances and systemic T cell deficiencies [162] and prevent colitis in mouse model induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS) [163]. Although the application of bacterial genetic engineering in IBS has not been reported in the literature, considering the close relationship between intestinal microbiota and IBS, it may be a potential and promising treatment strategy.

7. Conclusions and Perspective

There is considerable and growing evidence indicating the significance of interactions between gut microbiota and BAs in patients and animal models with IBS-D during recent years, but still, many blind spots about gut microbiota-bile acid axis with IBS-D should need to be explored. In this review, we have highlighted the intricate connection among bile acids, gut microbiota, and IBS-D, including summarizing the changes of gut microbiota in IBS-D patients, the effects of changing the gut microbiota on BA synthesis and metabolism, and the possible pathogenesis of BAs and their receptors involved in IBS-D. Moreover, given the substantial preclinical evidence for both top-down and bottom-up signaling within the gut microbiota-bile acid axis and the latest findings from clinical researches, it is a promising way to develop BA signaling and microorganisms as a target for the treatment of IBS-D.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

Kai Zhan, Huan Zheng, Jianqing Li, and Haomeng Wu contributed equally to this study.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (grant number 81703992, 81974563, and 81904148), Young innovative talents project of general colleges and universities in Guangdong Province (2019KQNCX023), Guangdong Medical Science and Technology Research Fund Project (A2020181), Key research projects of Guangzhou University of Chinese Medicine (XK-2019027), Guangdong Medical Science and Technology Research Fund Project (A2017394), and special fund for scientific and technological research of Traditional Chinese medicine of Guangdong Provincial Hospital of Chinese Medicine (YN2016QJ14).

References

[1] C. Kibune Nagasako, C. Garcia Montes, S. L. Silva Lorena, and M. A. Mesquita, “Irritable bowel syndrome subtypes: clinical and psychological features, body mass index and comorbidities,” Revista Española de Enfermedades Digestivas, vol. 108, pp. 59–64, 2015.
[2] R. L. S. Soares, “Irritable bowel syndrome: a clinical review,” World Journal of Gastroenterology, vol. 20, no. 34, pp. 12144–12160, 2014.
[3] B. Lacy, F. Mearin, L. Chang et al., “Bowel disorders,” Gastroenterology, vol. 150, no. 6, pp. 1393–1407.e5, 2016.
[4] Collaboration group of gastrointestinal functional diseases, branch of Gastroenterology, Chinese Medical Association, J.-S. Liu, L.-S. Xiong, and X.-L. Zuo, “Expert consensus on irritable bowel syndrome in China (Shanghai, 2015),” Chinese Journal of Digestive, vol. 36, no. 5, pp. 299–312, 2016.
[5] S. A. Joyce and C. G. M. Gahan, “Disease-associated changes in bile acid profiles and links to altered gut microbiota,” Digestive Diseases, vol. 35, no. 3, pp. 169–177, 2017.
[6] J. K. Nicholson, E. Holmes, J. Kinross, R. Burcelin, G. Gibson, and J. Wei, “Host-gut microbiota metabolic interactions,” Science, vol. 336, no. 6086, pp. 1262–1267, 2012.
[7] W. Jia, H. Li, L. Zhao, and J. K. Nicholson, "Gut microbiota: a potential new territory for drug targeting," *Nature Reviews Drug Discovery*, vol. 7, no. 2, pp. 123–129, 2008.

[8] E. Jia, Z. Liu, M. Pan, J. Lu, and Q. Ge, "Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases," *Journal of Zhejiang University-Science B*, vol. 20, no. 10, pp. 781–792, 2019.

[9] W. Jia, G. Xie, and W. Jia, "Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis," *Nature Reviews Gastroenterology & Hepatology*, vol. 15, no. 2, pp. 111–128, 2018.

[10] J. Singh, R. Metrani, S. Shivanagoudar, G. Jayaprakasha, and B. Patil, "Review on bile acids: effects of the gut microbiome, interactions with dietary fiber, and alterations in the bioaccessibility of bioactive compounds," *Journal of Agricultural and Food Chemistry*, vol. 67, no. 33, pp. 9124–9138, 2019.

[11] J. S. Lasa, I. Zubiaurre, I. Fanjul, P. Olivera, and L. Soifer, "Small intestinal bacterial overgrowth prevalence in celiac disease patients is similar in healthy subjects and lower in irritable bowel syndrome patients," *Revista de Gastroenterología de México (English Edition)*, vol. 80, no. 2, pp. 171–174, 2015.

[12] K. B. M. S. Islam, S. Fukiya, M. Hagio et al., "Bile acid is a host factor that regulates the composition of the cecal microbiota in rats," *Gastroenterology*, vol. 141, pp. 1773–1781, 2012.

[13] K. T. Suk and D. J. Kim, "Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease," *Expert Review of Gastroenterology & Hepatology*, vol. 13, no. 3, pp. 193–204, 2019.

[14] L. Zhao, W. Yang, F. Huang et al., "A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome," *Journal of Clinical Investigation*, vol. 130, 2020.

[15] P. I. Costea, F. Hildebrand, M. Arumugam et al., "Enterotypes in the landscape of gut microbial community composition," *Nature Microbiology*, vol. 3, no. 1, pp. 8–16, 2018.

[16] T. Liu, X. Song, S. Khan et al., "The gut microbiota at the intersection of bile acids and intestinal carcinogenesis: an old story, yet mesmerizing," *International Journal of Cancer*, vol. 146, pp. 1780–1790, 2019.

[17] A. Dance, "Transit time," *Nature*, vol. 533, no. 7603, pp. 5102–5103, 2016.

[18] C. Chang, "Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin," *Clinical and Experimental Gastroenterology*, vol. 11, pp. 335–345, 2018.

[19] X. Zhuang, Z. Tian, L. Li, Z. Zeng, M. Chen, and L. Xiong, "Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome," *Frontiers in Microbiology*, vol. 9, 2018.

[20] Z. Wang, C.-M. Xu, Y.-X. Liu et al., "Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome," *Chinese Medical Journal*, vol. 132, no. 8, pp. 889–904, 2019.

[21] H.-M. Zhu, L. Li, S.-Y. Li, Q. Yan, and F. Li, "Effect of water extract from Berberis heteropoda Schrenk roots on diarrhea-predominant irritable bowel syndrome by adjusting intestinal flora," *Journal of Ethnopharmacology*, vol. 237, pp. 182–191, 2019.

[22] I. Carroll, T. Ringel-Kulka, J. Siddle, and Y. Ringel, "Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome," *Neurogastroenterology & Motility*, vol. 24, no. 6, p. 521, 2012.

[23] K. Leventogiannis, P. Gkolfakis, G. Spithakis et al., "Correction to: effect of a preparation of four probiotics on symptoms of patients with irritable bowel syndrome: association with intestinal bacterial overgrowth," *Probiotics and Antimicrobial Proteins*, vol. 11, pp. 1–3, 2019.

[24] H. L. Huang, H. T. Chen, Q. L. Luo et al., "Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota," *Journal of Digestive Diseases*, vol. 20, no. 8, pp. 401–408, 2019.

[25] W. R. Wikoﬀ, A. T. Anfora, J. Liu et al., "Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites," *Proceedings of the National Academy of Sciences*, vol. 106, no. 10, pp. 3698–3703, 2009.

[26] K. Sjögren, C. Engdahl, P. Henning et al., "The gut microbiota regulates bone mass in mice," *Journal of Bone and Mineral Research*, vol. 27, no. 6, pp. 1357–1367, 2012.

[27] J. Li, H. Cui, Y. Cai et al., "Tong-Xie-Yao-Fang regulates 5-HT level in diarrhea predominant irritable bowel syndrome through gut microbiota modulation," *Frontiers in Pharmacology*, vol. 9, p. 1110, 2018.

[28] W. Atkinson, L. A. Houghton, P. J. Whorwell, and P. Whittaker, "Gender differences in plasma 5-hydroxytryptamine (5-HT) concentration in diarrhoea predominant irritable bowel syndrome (d-IBS): influence of the menstrual cycle," *Gastroenterology*, vol. 124, no. 4, p. A388, 2003.

[29] J. M. Yano, K. Yu, G. P. Donaldson et al., "Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis," *Cell*, vol. 161, no. 2, pp. 264–276, 2015.

[30] A. Hadijvasilis, C. Tsioitis, A. Michalinos, D. Ntourakis, D. K. Christodoulou, and A. P. Agouridis, "Bile acid is a host factor that regulates the composition of the cecal microbiota in rats," *Gastroenterology*, vol. 141, pp. 1773–1781, 2012.

[31] S. Fukuda, H. Toh, K. Hase et al., "Bifidobacteria can protect from enteropathogenic infection through production of acetate," *Nature*, vol. 469, no. 7331, pp. 543–547, 2011.

[32] M. Majeed, K. Nagabhushanam, S. Natarajan et al., "Baclillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double-blind randomized placebo-controlled pilot clinical study," *Nutrition Journal*, vol. 15, p. 21, 2015.

[33] M. Majeed, K. Nagabhushanam, S. Arumugam, and F. Ali, "Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof," US application No. 14839923 and PCT/US2015/47608, 2015, US application No. 14839923 and PCT/US2015/47608, 2015.

[34] R. Duan, S. Zhu, B. Wang, and L. Duan, "Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: a systematic review," *Clinical and Translational Gastroenterology*, vol. 10, no. 2, article e00012, 2019.

[35] X. Zhuang, L. Xiong, L. Li, M. Li, and M. Chen, "Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis," *Journal of Gastroenterology and Hepatology*, vol. 32, 2017.
P. Eckburg, E. Bik, C. Bernstein et al., R. E. Ley, D. A. Peterson, and J. I. Gordon, M. Begley, C. Gahan, C. Hill, M. Begley, C. G. Gahan, and J. Winston and C. Theriot, J. P. Chae, V. D. Valeriano, G.-B. Kim, and D.-K. Kang, J. Ridlon, S. Harris, S. Bhowmik, D.-J. Kang, and P. Hylemon, C. M. Franz, I. Specht, P. Haberer, and W. H. Holzapfel, J. M. Ridlon, D. J. Kang, P. B. Hylemon, and J. S. Bajaj, L. Caballería, M. A. Auladell, P. Torán et al., T. Kanda, L. Foucand, Y. Nakamura et al., R. N. Appleby and J. R. F. Walters, R. Spiller, Q. Aziz, F. Creed et al., N. J. Talley, V. Stanghellini, R. C. Heading, K. L. Koch, J. R. Malagelada, and G. N. Tytgat, R. Spiller, Q. Aziz, F. Creed et al., S. Wang, W. Dong, L. Liu et al., S. Wang, W. Dong, L. Liu et al., S. J. Keely, M. M. Scharl, L. S. Bertelsen, L. R. Hagey, F. Yang, L. Luo, Y. Liu et al., B. S. Wong, M. Camilleri, P. J. Carlson et al., B. S. Wong, and A. R. Zinsmeister, S. J. Keely, M. M. Scharl, L. S. Bertelsen, L. R. Hagey, F. Yang, L. Luo, Y. Liu et al., B. S. Wong, M. Camilleri, P. J. Carlson et al., B. S. Wong, and A. R. Zinsmeister, H. Duboc, S. Rajca, D. Rainteau et al., H. Duboc, S. Rajca, D. Rainteau et al., M. Camilleri, I. Busciglio, A. Acosta et al., M. Camilleri, I. Busciglio, A. Acosta et al., P. Eckburg, E. Bik, C. Bernstein et al., R. E. Ley, D. A. Peterson, and J. I. Gordon, P. Eckburg, E. Bik, C. Bernstein et al., R. E. Ley, D. A. Peterson, and J. I. Gordon, M. Begley, C. Gahan, C. Hill, M. Begley, C. G. Gahan, and C. Hill, “The interaction between bacteria and bile,” M. Begley, C. Gahan, C. Hill, M. Begley, C. G. Gahan, and C. Hill, “The interaction between bacteria and bile,” J. P. Chae, V. D. Valeriano, G.-B. Kim, and D.-K. Kang, J. P. Chae, V. D. Valeriano, G.-B. Kim, and D.-K. Kang, “Molecular cloning, characterization and comparison of bile salt hydrolases from Lactobacillus johnsonii PF01,” J. P. Chae, V. D. Valeriano, G.-B. Kim, and D.-K. Kang, J. P. Chae, V. D. Valeriano, G.-B. Kim, and D.-K. Kang, “Molecular cloning, characterization and comparison of bile salt hydrolases from Lactobacillus johnsonii PF01,” A. Kriaa, M. Bourgin, A. Potiron et al., A. Kriaa, M. Bourgin, A. Potiron et al., “Microbial impact on cholesterol and bile acid metabolism: current status and future prospects,” A. Kriaa, M. Bourgin, A. Potiron et al., A. Kriaa, M. Bourgin, A. Potiron et al., “Microbial impact on cholesterol and bile acid metabolism: current status and future prospects,” P. Dawson and S. Karpen, P. Dawson and S. Karpen, “Intestinal transport and metabolism of bile acids,” P. Dawson and S. Karpen, P. Dawson and S. Karpen, “Intestinal transport and metabolism of bile acids,” L. Caballería, M. A. Auladell, P. Torán et al., L. Caballería, M. A. Auladell, P. Torán et al., “Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study,” L. Caballería, M. A. Auladell, P. Torán et al., “Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study,” R. L. Chiang, R. L. Chiang, “Bile acids: regulation of synthesis,” R. L. Chiang, R. L. Chiang, “Bile acids: regulation of synthesis,” T. Kanda, L. Foucand, Y. Nakamura et al., T. Kanda, L. Foucand, Y. Nakamura et al., “Regulation of expression of human intestinal bile acid-binding protein in Caco-2 cells,” T. Kanda, L. Foucand, Y. Nakamura et al., “Regulation of expression of human intestinal bile acid-binding protein in Caco-2 cells,”
[69] S. T. Onduśni-Shiyanbade, M. Camilleri, S. McKinzie et al., “Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function,” Clinical Gastroenterology and Hepatology, vol. 8, no. 2, pp. 159–165.e5, 2010.

[70] P. A. Bampton, P. G. Dinning, M. L. Kennedy, D. Z. Lubowski, and I. J. Cook, “The proximal colonic motor response to rectal mechanical and chemical stimulation,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 282, no. 3, pp. G443–G449, 2002.

[71] F. Yang, L. Luo, Z.-D. Zhu et al., “Chlorogenic acid inhibits liver fibrosis by blocking the miR-21-regulated TGF-β1/Smad7 signaling pathway in vitro and in vivo,” Frontiers in Pharmacology, vol. 8, p. 929, 2017.

[72] A. S. Rao, B. S. Wong, M. Camilleri et al., “Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis,” Gastroenterology, vol. 139, no. 5, pp. 1549–1558.e1, 2010.

[73] G. Zollner, M. Wagner, and M. Trauner, “Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity,” Pharmacology & Therapeutics, vol. 126, no. 3, pp. 228–243, 2010.

[74] J. R. Mora, M. Ivata, and U. H. von Andrian, “Vitamin effects on the immune system: vitamins A and D take centre stage,” Nature Reviews Immunology, vol. 8, no. 9, pp. 685–698, 2008.

[75] A. Di Ciavula, G. Garruti, R. Baccetto et al., “Bile acid physiology,” Annals of Hepatology, vol. 16, pp. S4–14, 2017.

[76] T. Maruyama, Y. Miyamoto, T. Nakamura et al., “Identification of membrane-type receptor for bile acids (M-BAR),” Biochemical and Biophysical Research Communications, vol. 298, no. 5, pp. 714–719, 2002.

[77] Y. Kawamata, R. Fujii, M. Hosoya et al., “A G protein-coupled receptor responsive to bile acids,” Journal of Biological Chemistry, vol. 278, no. 11, pp. 9435–9440, 2003.

[78] P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels, “Role of bile acids and bile acid receptors in metabolic regulation,” Physiological Reviews, vol. 89, no. 1, pp. 147–191, 2009.

[79] C. J. Sinal, M. Tohkin, M. Miyata, J. M. Ward, G. Lambert, and F. J. Gonzalez, “Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis,” Cell, vol. 102, no. 7, pp. 731–744, 2000.

[80] S. I. Sayin, A. Wahlstrom, J. Felin et al., “Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist,” Cell Metabolism, vol. 17, no. 2, pp. 225–235, 2013.

[81] A. Wahlstrom, S. I. Sayin, H.-U. Marshall, and F. Bäckhed, “Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism,” Cell Metabolism, vol. 24, no. 1, pp. 41–50, 2016.

[82] M. Mazidi, P. Caravatto, J. Speakman, and R. Cohen, “Mechanisms of action of surgical interventions on weight-related diseases: the potential role of bile acids,” Obesity Surgery, vol. 27, no. 3, pp. 826–836, 2017.

[83] C. Degirolamo, S. Rainaldi, F. Bovenga, S. Murzilli, and A. Moschetta, “Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice,” Cell Reports, vol. 7, no. 1, pp. 12–18, 2014.

[84] T. Inagaki, A. Moschetta, Y.-K. Lee et al., “Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor,” Proceedings of the National Academy of Sciences, vol. 103, no. 10, pp. 3920–3925, 2006.

[85] M. Camilleri, P. Carlson, A. Acosta et al., “RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 306, no. 12, pp. G1089–G1098, 2014.

[86] M. Camilleri, P. Carlson, A. Acosta, and I. Busciglio, “Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 309, no. 1, pp. G10–G20, 2015.

[87] T. Horikawa, T. Oshima, M. Li et al., “Chenodeoxycholic acid releases proinflammatory cytokines from small intestinal epithelial cells through the farnesoid X receptor,” Digestion, vol. 100, no. 4, pp. 286–294, 2019.

[88] P. Vavassori, A. Mencarelli, B. Renga, E. Distritti, and S. Fiorucci, “The bile acid receptor FXR is a modulator of intestinal innate immunity,” The Journal of Immunology, vol. 183, no. 10, pp. 6251–6261, 2009.

[89] W.-T. Li, Q.-Q. Luo, B. Wang et al., “Bile acids induce visceral hypersensitivity via mucosal mast cell-to-nociceptor signaling that involves the farnesoid X receptor/nerve growth factor/transient receptor potential vanilloid 1 axis,” The FASEB Journal, vol. 33, pp. 2435–2450, 2018.

[90] J. M. Lee, M. Wagner, R. Xiao et al., “Nutrient-sensing nuclear receptors coordinate autophagy,” Nature, vol. 516, no. 7529, pp. 112–115, 2014.

[91] L. Yang, C. Liu, W. Zhao et al., “Impaired autophagy in intestinal epithelial cells alters gut microbiota and host immune responses,” Applied and Environmental Microbiology, vol. 84, no. 18, 2018.

[92] T. Inagaki, M. Choi, A. Moschetta et al., “Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis,” Cell Metabolism, vol. 2, no. 4, pp. 217–225, 2005.

[93] M. J. Potthoff, S. A. Kliwer, and D. J. Mangelsdorf, “Endocrine fibroblast growth factors 15/19 and 21: from feast to famine,” Genes & Development, vol. 26, no. 4, pp. 312–324, 2012.

[94] P. Vijayvargiya, M. Camilleri, P. Carlson et al., “Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea,” Alimentary Pharmacology & Therapeutics, vol. 46, no. 6, pp. 581–588, 2017.

[95] L. Gonzalez-Mariscal, R. Tapia, and D. Chamorro, “Crosstalk of tight junction components with signaling pathways,” Biochimica et Biophysica Acta (BBA) - Biomembranes, vol. 1778, no. 3, pp. 729–756, 2008.

[96] E. Cario, G. Gerken, and D. K. Podolsky, “Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C,” Gastroenterology, vol. 127, no. 1, pp. 224–238, 2004.

[97] G. Feldman, B. Kiely, N. Martin, G. Ryan, T. McMorrow, and M. P. Ryan, “Role for TGF-beta in cyclosporine-induced modulation of renal epithelial barrier function,” Journal of the American Society of Nephrology, vol. 18, no. 6, pp. 1662–1671, 2007.
junction structure,” Journal of Cell Science, vol. 119, no. 10, pp. 2095–2106, 2006.

[99] K. L. Howe, C. Beardon, A. Wang, A. Nazli, and D. M. McKay, “Transforming growth factor-β regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157: H7-induced increased permeability,” The American Journal of Pathology, vol. 167, no. 6, pp. 1587–1597, 2005.

[100] D. Medici, E. Hay, and D. Goodenough, “Cooperation between snail and LEF-1 transcription factors is essential for TGF-β1-induced epithelial-mesenchymal transition,” Molecular Biology of the Cell, vol. 17, no. 4, pp. 1871–1879, 2006.

[101] C. Dai, D.-H. Zhao, and M. Jiang, “VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling pathways,” International Journal of Molecular Medicine, vol. 29, pp. 202–208, 2011.

[102] V. Keitel, M. Donner, S. Winandy, R. Kubitz, and D. Häussinger, “Expression and function of the bile acid receptor TGR5 in Kupffer cells,” Biochemical and Biophysical Research Communications, vol. 372, no. 1, pp. 78–84, 2008.

[103] A. Baars, A. Oosting, J. Knol, J. Garssen, and J. van Bergenheegouwen, “The gut microbiota as a therapeutic target in IBD and metabolic disease: a role for the bile acid receptors FXR and TGR5,” Microorganisms, vol. 3, no. 4, pp. 641–666, 2015.

[104] F. S. van Nierop, M. J. Scheltema, H. M. Eggink et al., “Clinical relevance of the bile acid receptor TGR5 in metabolism,” The Lancet Diabetes & Endocrinology, vol. 5, no. 3, pp. 224–233, 2017.

[105] P. Pathak, C. Xie, R. G. Nichols et al., “Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism,” Hepatology, vol. 68, no. 4, pp. 1574–1588, 2018.

[106] S. Cipriani, A. Mencarelli, M. G. Chini et al., “The bile acid receptor GpBAR1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis,” PLoS One, vol. 6, no. 10, article e25637, 2011.

[107] J. R. Turner, “Intestinal mucosal barrier function in health and disease,” Nature Reviews Immunology, vol. 9, no. 11, pp. 799–809, 2009.

[108] S. Abu-Farsakh, T. Wu, A. Lalonde, J. Sun, and Z. Zhou, “High expression of Claudin-2 in esophageal carcinoma and precancerous lesions is significantly associated with the bile salt receptors VDR and TGR5,” BMC Gastroenterology, vol. 17, no. 1, p. 33, 2017.

[109] J. I. Yang, J.-H. Yoon, S. J. Myung et al., “Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes,” Biochemical and Biophysical Research Communications, vol. 361, no. 1, pp. 156–161, 2007.

[110] R. Sharma, C. Young, and J. Neu, “Molecular modulation of intestinal epithelial barrier: contribution of microbiota,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 305879, 15 pages, 2010.

[111] C. Pellegrini, L. Antonioli, R. Colucci, C. Blandizzi, and M. Fornai, “Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?,” Acta Neuropathologica, vol. 136, no. 3, pp. 345–361, 2018.
E. Distrutti, S. Cipriani, A. Mencarelli, B. Renga, and Y.-J. Li, C. Dai, and M. Jiang, “14 BioMed Research International”.

O. McAuliffe, M.-X. Chen, Y. Chen, R. Fu, S.-Y. Liu, Q.-Q. Yang, and T.-A. C. Ford, P. Moayyedi, W. D. Chey et al., “G. Barbara, C. Cremon, and F. Azpiroz, “Probiotics in irritable bowel syndrome: where are we?,” Neurogastroenterology & Motility, vol. 30, no. 12, article e13513, 2018.

A. C. Ford, M. A. Harris, B. E. Lacy, E. M. M. Quigley, and P. Moayyedi, “Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome,” American Journal of Gastroenterology, vol. 113, Suppl 2, pp. 1–18, 2018.

A. C. Ford, L. A. Harris, E. M. M. Quigley, and P. Moayyedi, “M. Ng, F. Lam, T. Lam et al., “Sa2057 probiotic bacteria VSL#3 alter visceral sensitivity and mucosa-associated intestinal microbiota in patients with irritable bowel syndrome,” Gastroenterology, vol. 142, no. 5, pp. S–391, 2012.

Y.-J. Li, C. Dai, and M. Jiang, “Mechanisms of probiotic VSL#3 in a rat model of visceral hypersensitivity involves the mast cell-PAR2-TRPV1 pathway,” Digestive Diseases and Sciences, vol. 64, no. 5, pp. 1182–1192, 2019.

E. Distrutti, S. Cipriani, A. Mencarelli, B. Renga, and S. Fiorucci, “Probiotics VSL#3 protect against visceral pain in murine model of irritable bowel syndrome,” PLoS One, vol. 8, no. 5, article e63893, 2013.

O. McAuliffe, R. J. Cano, and T. R. Klaenhammer, “Genetic analysis of two bile salt hydrolase activities in Lactobacillus acidophilus NCFM,” Applied and Environmental Microbiology, vol. 71, no. 8, pp. 4925–4929, 2005.

N. Pavlovic, K. Stankov, and M. Miko, “Probiotics—interactions with bile acids and impact on cholesterol metabolism,” Applied Biochemistry and Biotechnology, vol. 168, no. 7, pp. 1880–1892, 2012.

J. H. Oh, Y. S. Jang, D. Kang, D. K. Chang, and Y. W. Min, “Efficacy and safety of new Lactobacilli probiotics for unconstipated irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial,” Nutrients, vol. 11, no. 12, p. 2887, 2019.

K. Ray, “Mindful of probiotics for psychiatric comorbidities in IBS,” Nature Reviews Gastroenterology & Hepatology, vol. 14, no. 7, pp. 386–387, 2017.

A. Agrawal, L. A. Houghton, J. Morris et al., “Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation,” Alimentary Pharmacology & Therapeutics, vol. 29, no. 1, pp. 104–114, 2009.

T. Pérez-Berezo, J. Pujo, P. Martin et al., “Identification of an analgesic lipopeptide produced by the probiotic Escherichia coli strain Nissle 1917,” Nature Communications, vol. 8, no. 1, p. 1314, 2017.

H. F. Dale, S. H. Rasmussen, Ó. Ó. Asiller, and G. A. Lied, “Probiotics in irritable bowel syndrome: an up-to-date systematic review,” Nutrients, vol. 11, no. 9, p. 2048, 2019.

H.-L. Niu and J.-Y. Xiao, “The efficacy and safety of probiotics in patients with irritable bowel syndrome: evidence based on 35 randomized controlled trials,” International Journal of Surgery, vol. 75, pp. 116–127, 2020.

A. C. Ford, “Stool as a treatment for IBS: more questions than answers?,” The Lancet Gastroenterology & Hepatology, vol. 3, no. 1, pp. 2–3, 2018.

P. H. Johnsen, F. Hölööpä, P. C. Valle, and R. Goll, “The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: secondary endpoints of a double blind, randomized, placebo-controlled trial,” EBioMedicine, vol. 51, p. 102562, 2020.

T. Mazzawi, Ø. Ekrem, G. A. Lied, and T. Hausken, “Abnormal urogynaecological immune cells density in the duodenum of patients with diarrhea-predominant irritable bowel syndrome changes following fecal microbiota transplantation,” Gastroenterology Research and Practice, vol. 2020, Article ID 3520668, 9 pages, 2020.

W. Sun, Y. Guo, S. Zhang et al., “Fecal microbiota transplantation can alleviate gastrointestinal transit in rats with high-fat diet-induced obesity via regulation of serotonin biosynthesis,” BioMed Research International, vol. 2018, Article ID 8308671, 9 pages, 2018.

D. Xu, V. Chen, C. Steiner et al., “Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis,” The American Journal of Gastroenterology, vol. 114, no. 7, pp. 1043–1050, 2019.

K. Myneedu, A. Deoker, M. J. Schmulson, and M. Bashashati, “Fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis,” United European Gastroenterology Journal, vol. 7, no. 8, pp. 1033–1041, 2019.

S. I. Halkjær, A. W. Boolsen, S. Günther, A. H. Christensen, and A. M. Petersen, “Can fecal microbiota transplantation cure irritable bowel syndrome?,” World Journal of Gastroenterology, vol. 23, no. 22, pp. 4112–4120, 2017.

Y. Wang, F. Zheng, S. Liu, and H. Luo, “Research progress in fecal microbiota transplantation as treatment for irritable bowel syndrome,” Gastroenterology Research and Practice, vol. 2019, Article ID 9759138, 8 pages, 2019.

R. E. Oostevaa, E. M. Terveer, H. W. Verspaget, E. J. Kuijper, and J. J. Keller, “Clinical application and potential of fecal microbiota transplantation,” Annual Review of Medicine, vol. 70, no. 1, pp. 355–351, 2019.

B. S. Wong, M. Camilleri, P. Carlson et al., “Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea,” Clinical Gastroenterology and Hepatology, vol. 10, no. 9, p. 1009, 2012.

W. Kramer and H. Glombik, “Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs,” Current Medicinal Chemistry, vol. 13, no. 9, pp. 997–1016, 2006.
[186] G. Kim, F. Deepinder, W. Morales et al., “Methanobrevibacter smithii is the predominant methanogen in patients with constipation-predominant IBS and methane on breath,” *Digestive Diseases and Sciences*, vol. 57, no. 12, pp. 3213–3218, 2012.

[187] J. Tap, M. Derrien, H. Törnblom et al., “Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome,” *Gastroenterology*, vol. 152, no. 1, pp. 111–123.e8, 2017.